Physician profile
John R Stuart
NPI 1235195439
$4,120.25
in general payments reported to CMS, 2019-2025
32 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $583 · 2021: $212 · 2022: $688 · 2023: $601 · 2024: $948 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.98 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.94 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $508.96 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $482.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $266.47 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $226.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.20 | 2019-2024 | Jardiance |
| Amgen INC. | $173.61 | 2020-2023 | Evenity, Prolia |
| Amarin Pharma, INC. | $138.42 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.24 | 2022-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $120.91 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $101.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $100.41 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $98.02 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Nevro Corp. | $84.76 | 2022 | |
| Allergan, INC. | $80.42 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $76.71 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $67.10 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Phathom Pharmaceuticals, INC. | $66.74 | 2024 | Voquezna |
| Abbott Laboratories | $63.55 | 2022-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $56.70 | 2019-2020 | |
| Sanofi Pasteur INC. | $51.46 | 2024 | |
| Axsome Therapeutics, INC. | $29.58 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $27.64 | 2024 | |
| Daiichi Sankyo INC. | $24.71 | 2022 | |
| Inspire Medical Systems, INC. | $24.25 | 2025 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $23.69 | 2025 | Neffy |
| Grifols USA, LLC | $17.51 | 2023 | Prolastin-C Liquid |
| Coopersurgical, INC. | $17.08 | 2025 | Paragard T 380a |
| Axonics, INC. | $15.63 | 2022 | |
| Angiodynamics, INC. | $13.94 | 2024 | Auryon Laser System 100-120 Vac |
| Ferring Pharmaceuticals INC. | $13.81 | 2024 | Euflexxa |
| E.R. Squibb & Sons, L.L.C. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.